Study Summary
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
Want to learn more about this trial?
Request More InfoInterventions
FT836DRUG
FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.
PaclitaxelDRUG
IV infusion ; 80 mg/m2 QW; Days -21, -14, and -7
CetuximabDRUG
Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion
TrastuzumabDRUG
trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Southern California | La Jolla | California | United States |
| UC San Diego Moores Cancer Center | La Jolla | California | United States |
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | United States |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | United States |
| M. D. Anderson Cancer Center | Houston | Texas | United States |